Raymond James analyst Christopher Raymond raised the firm’s price target on Regeneron (REGN) to $723 from $673 and keeps an Outperform rating on the shares. The company reported a “strong” Q3 beat with Eylea and Dupixent both beating estimates handily, the analyst tells investors in a research note. The firm thinks Regeneron’s alternative-source plans regarding the Catalent facility was the big news from the earnings call. It continues to recommend buying Regeneron shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron price target raised to $767 from $756 at Morgan Stanley
- Midday Fly By: OpenAI signs new Microsoft deal, PayPal reports Q3 beat
- Early notable gainers among liquid option names on October 28th
- Morning Movers: UPS and PayPal jump following quarterly reports
- Regeneron reports Q3 non-GAAP EPS $11.83, consensus $9.64